Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis


      Background: A new class of topical receptor-selective acetylenic retinoids, the first of which is tazarotene, has been developed. Objective: Our purpose was to compare the safety, efficacy, and duration of therapeutic effect of 12 weeks of once-daily tazarotene 0.1% and 0.05% gel with that of twice-daily fluocinonide 0.05% cream in the treatment of patients with plaque psoriasis. Methods: Three hundred forty-eight patients with plaque psoriasis were enrolled and 275 patients completed a multicenter, investigator-masked, randomized, parallel-group clinical trial. Results: Both tazarotene gels were as effective as fluocinonide in reducing plaque elevation after 1 week of treatment, and tazarotene 0.1% gel was similar to fluocinonide in reducing scaling of trunk/limb lesions at all study weeks except week 4. Tazarotene 0.1% gel was similar to fluocinonide in reducing scaling of knee/elbow lesions at weeks 8 and 12. Fluocinonide had a significantly greater effect on erythema than tazarotene at weeks 2 through 8. However, treatments were not significantly different at week 12, and tazarotene demonstrated significantly better maintenance of therapeutic effect after cessation of therapy. Conclusion: Tazarotene 0.1% and 0.05% gels were safe and effective in the treatment of mild-to-moderate plaque psoriasis.(J Am Acad Dermatol 1998;38:705-11.)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Liem WH
        • McCullough JL
        • Weinstein GD
        Is topical therapy effective for psoriasis? Results of a survey of U.S. dermatologists [abstract].
        Clin Res. 1992; 40: 495A
        • Stoughton RB
        • Cornell RL
        Review of super-potent topical corticosteroids.
        Semin Dermatol. 1987; 6: 72-76
        • Johns AM
        • Bower BD
        Wasting of napkin area after repeated use of fluorinated steroid ointment.
        Br Med J. 1970; 1: 347
        • Stenmovic DV
        Corticosteroid-involved atrophy of the skin with telangiectasia: a clinical and experimental study.
        Br J Dermatol. 1972; 87: 548-556
        • Pascher F
        Systemic reactions to topically applied drugs.
        Int J Dermatol. 1978; 17: 768-775
        • Keipert JA
        • Kelly R
        Temporary Cushing’s syndrome from percutaneous absorption of betamethasone 17-valerate.
        Med J Aust. 1971; 1: 542-544
        • Walsh P
        • Aeling JL
        • Huff L
        • Weston WL
        Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids.
        J Am Acad Dermatol. 1993; 29: 501-503
        • Du Vivier A
        Tachyphylaxis to topically applied steroids.
        Arch Dermatol. 1976; 112: 1245-1248
        • Fisher DA
        Adverse effects of topical corticosteroid use.
        West J Med. 1995; 162: 123-126
        • Esgleyes-Ribot T
        • Chandraratna RA
        • Lew-Kaya D
        • Sefton J
        • Duvic M
        Response of psoriasis to a new topical retinoid, AGN190168.
        J Am Acad Dermatol. 1994; 30: 581-590
        • Ellis CN
        • Voorhees JJ
        Etretinate therapy.
        J Am Acad Dermatol. 1987; 16: 267-291
        • Chandraratna RAS
        Tazarotene: first of a new generation of receptor-selective retinoids.
        Br J Dermatol. 1996; 135: 18-25
        • Lew-Kaya DA
        • Sefton J
        • Krueger GG
        • et al.
        Safety and efficacy of a new retinoid gel in the treatment of psoriasis [abstract].
        J Invest Dermatol. 1992; 92: 600
        • Weinstein GD
        • Green L
        • Drake LA
        • et al.
        New topical retinoid gel for therapy of psoriasis: dose-ranging study of AGN 190168 [abstract].
        J Invest Dermatol. 1993; 100: 544
        • Weinstein G
        Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis.
        Br J Dermatol. 1996; 135: 32-36
        • Weinstein G
        • Krueger GG
        • Lowe NJ
        • Duvic M
        • Friedman DJ
        • Jegasothy BV
        • et al.
        Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect.
        J Am Acad Dermatol. 1997; 37: 85-92
        • George SL
        • Desu MM
        Planning the size and duration of a clinical trial studying the time to some critical event.
        J Chron Dis. 1974; 27: 15-24
        • Afifi A
        • Azen S
        Statistical analysis, a computer-oriented approach.
        in: Academic Press, New York1972: 162-165
        • Peace K
        Biopharmaceutical statistics for drug development.
        in: Marcel Dekker, New York1988: 415-421
        • Kalbfleisch J
        • Prentice R
        The statistical analysis of failure time data.
        John Wiley & Sons, New York1980
        • Milliken G
        • Johnson D
        Analysis of mess data; vol 1: designed experiments.
        Lifetime Learning Publications, Belmont (CA)1984
      1. SAS User’s Guide. Statistics; version 6. SAS Institute, Cary (NC)1990
      2. Statistical Analysis System VAX version 6.08. SAS Institute, Cary (NC)1990